Advertisement

Inflammatory bowel disease associated with the combination treatment of nivolumab and metformin: data from the FDA adverse event reporting system

  • Huaqiang Zhou
  • Jiaqing Liu
  • Yaxiong Zhang
  • Li Zhang
Short Communication

Abstract

Purpose

PD-1/PD-L1 inhibitors have demonstrated unparalleled therapeutic efficacy in multiple tumor types. Additionally, metformin has been linked to favorable outcomes in tumors. Many researchers have reported immune-mediated adverse events induced by immune checkpoint inhibitors (ICI) single agent. However, little is documented on the adverse events of the combined use of ICI and metformin.

Methods

To address this question, we used the Food and Drug Administration Adverse Event Reporting System (FAERS) to display the landscape of adverse events associated with the combined use of ICI and metformin. We identified 38 adverse event cases about the combination treatment between January 1, 2015 and June 30, 2018.

Results

There are 36 cases in patients receiving nivolumab plus metformin (NM) therapy, and the other 2 cases were pembrolizumab plus metformin (PM). Among the 36 patients receiving NM therapy, the most common indication was for treatment of malignant lung cancer (20, 55.56%), Notably, 9 cases of inflammatory bowel disease (IBD) and diarrhea were reported.

Conclusions

Our findings revealed that higher risk of IBD might occur in lung cancer patients during the combined therapy of nivolumab plus metformin. Further studies are needed to verify our findings.

Keywords

Immune checkpoint inhibitors Metformin Adverse event FAERS Inflammatory bowel disease 

Notes

Acknowledgements

Wenfeng Fang, Shaodong Hong, Gang Chen, Shen Zhao, Xi Chen, Zhonghan Zhang (all with the Sun Yat-sen University Cancer Center), provided data interpretation and critical revision of the manuscript. Yunpeng Yang, Yuanyuan Zhao, Yan Huang, and Hongyun Zhao (all with the Sun Yat-sen University Cancer Center), contributed excellent work to the conception and design of the study. None of these individuals received financial compensation.

Author contributions

LZ supervised this work. HZ, JL, YZ were responsible for the conception and design of the study, interpretation of data, drafting, and writing of the article. All authors participated in final approval of the article and agreed to be accountable for all aspects of the work.

Funding

This work was supported by: National Key R&D Program of China (Grant No. 2016YFC0905500, 2016YFC0905503). The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Compliance with ethical standards

Ethics approval and consent to participate

Institutional review board approval was waived for this study because FAERS is a public anonymized database.

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Wolchok JD (2015) PD-1 blockers. Cell 162(5):937CrossRefGoogle Scholar
  2. 2.
    Cha J-H, Yang W-H, Xia W et al (2018) Metformin promotes antitumor immunity via endoplasmic-reticulum-associated degradation of PD-L1. Mol Cell 71(4):606–20.e7CrossRefGoogle Scholar
  3. 3.
    Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378(2):158–168CrossRefGoogle Scholar
  4. 4.
  5. 5.
    Ng SC, Shi HY, Hamidi N et al (2018) Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 390(10114):2769–2778CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Medical OncologySun Yat-sen University Cancer CenterGuangzhouPeople’s Republic of China
  2. 2.State Key Laboratory of Oncology in South ChinaGuangzhouPeople’s Republic of China
  3. 3.Collaborative Innovation Center for Cancer MedicineGuangzhouPeople’s Republic of China
  4. 4.Zhongshan School of MedicineSun Yat-sen UniversityGuangzhouPeople’s Republic of China

Personalised recommendations